From Dysbiosis to Precision Therapy: Decoding the Gut-Bladder Axis in Bladder Carcinogenesis

ZE QIANG LIU¹XIAO YING YANG¹JIA HONG CHEN¹SI CHENG GE²SHI XUE DAI^3*SHENG HUANG ZHU⁴ZHI YONG XIAN⁴

• ¹Southern Medical University, Guangzhou, China
• ²Gannan Medical University, Ganzhou, China
• ³Guangdong Provincial People's Hospital, Guangzhou, China
• ⁴Guangdong Provincial People’s Hospital Ganzhou Hospital, Ganzhou, China

Abstract：The gut-bladder axis (GBA), a bidirectional network connecting gastrointestinal and urinary systems, has recently emerged as a pivotal focus in bladder cancer research. Beyond conventional risk factors, gut dysbiosis, aberrant microbial metabolites, and neuro-immune pathway disruptions have been implicated in tumorigenesis and progression. Short-chain fatty acids (SCFAs), microbial-derived metabolites, are shown to indirectly modulate tumor behavior through immune microenvironment regulation and inflammatory response attenuation.Cross-organ crosstalk is further mediated by neural pathways (e.g., vagal signaling) and shared receptors, including the Farnesoid X Receptor (FXR) and Toll-like Receptor 4 (TLR4). Novel therapies leveraging microbial ecology principles demonstrate potential, including immune checkpoint inhibitors combined with microbiota modulation (e.g., Parabacteroides distasonis-enhanced PD-1 efficacy), probiotics to reverse chemoresistance, and microbiota reprogramming for SCFA-targeted strategies.However, molecular mechanisms underlying GBA-host interactions remain poorly characterized. Clinical translation is hindered by limited cohort sizes and interindividual heterogeneity. Current studies, while revealing partial pathways, face methodological inconsistencies, particularly in urinary microbiome profiling, and a lack of longitudinal human data. Future breakthroughs will require multi-omics integration, organoid-based models, and interdisciplinary collaboration to address these gaps.